Opinion

Video

Patient Profile 1: A 70-Year-Old Man With PSMA-Positive mCRPC

Author(s):

Oliver Sartor, MD

Oliver Sartor, MD, discusses how a 70-year-old man with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) represents a typical candidate for PSMA-targeted imaging and potential radioligand therapy, considering factors such as disease progression, previous treatments, and overall health status in tailoring management strategies.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      The Growing Call for Combination Therapy in NMIBC Treatment
      The Growing Call for Combination Therapy in NMIBC Treatment
      Optimizing NMIBC Treatment Through Sequencing and Patient Preference
      Optimizing NMIBC Treatment Through Sequencing and Patient Preference
      1 expert is featured in this series.
      Managing Abiraterone Intolerance: Alternative Dosing Strategies in Practice
      1 expert is featured in this series.
      Decision-Making and Multidisciplinary Counseling for Nodal Involvement on PSMA PET
      Rethinking First-Line Treatments: Will BCG Continue to Be the Standard in NMIBC?
      Rethinking First-Line Treatments: Will BCG Continue to Be the Standard in NMIBC?
      In the Pipeline: Novel Treatment Delivery Methods for NMIBC
      In the Pipeline: Novel Treatment Delivery Methods for NMIBC
      Urology Times Mitomycin RX Review Square Thumb
      RX Review: Implementing mitomycin for LG-IR-NMIBC in clinical practice
      Urology Times Mitomycin RX Review Square Thumb
      RX Review: TURBT vs chemoablation for low-grade, intermediate-risk NMIBC
      Urology Times Mitomycin RX Review Square Thumb
      RX Review: A paradigm shift for low-grade, intermediate-risk NMIBC
      Urology Times Mitomycin RX Review Square Thumb
      RX Review: How mitomycin for intravesical solution works in treating LG-IR-NMIBC
      Related Content
      Patient talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
      July 10th 2025

      FDA grants breakthrough device designation for ArteraAI Prostate tool

      Benjamin P. Saylor Hannah Clarke
      “This designation is a powerful validation of our software's potential to transform how we treat cancer,” said Andre Esteva, CEO of Artera.
      Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD
      June 30th 2025

      Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

      Amy M. Pearlman, MD
      Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.
      FDA grants fast track designation to TRE-515 with 177Lu-PSMA-617 for mCRPC
      July 9th 2025

      FDA grants fast track designation to TRE-515 with 177Lu-PSMA-617 for mCRPC

      Benjamin P. Saylor Hannah Clarke
      The investigational treatment is being evaluated in phase 1 clinical trials for solid tumors.
      Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD
      June 19th 2025

      Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD

      Amy M. Pearlman, MD
      The conversation covers practical, case-based strategies for counseling MSM patients.
      Expanded indication sought for niraparib plus AAP in Europe
      July 7th 2025

      Expanded indication sought for niraparib plus AAP in Europe

      Hannah Clarke
      The application is supported by data from the phase 3 AMPLITUDE trial.
      Regulatory recap: FDA approvals in urology from the first half of 2025
      July 4th 2025

      Regulatory recap: FDA approvals in urology from the first half of 2025

      Hannah Clarke
      Take a look through all the regulatory milestones in urology from the first half of the 2025.
      © 2025 MJH Life Sciences

      All rights reserved.